uniQure (NASDAQ:QURE) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of uniQure (NASDAQ:QURE) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $25.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on the stock. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $20.00 to $52.00 in a report on Tuesday. StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. The Goldman Sachs Group lowered their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Cantor Fitzgerald upped their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Royal Bank of Canada lowered their price objective on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $27.33.

uniQure Stock Up 109.6 %

Shares of NASDAQ QURE opened at $15.30 on Tuesday. The business has a 50-day moving average price of $6.42 and a 200 day moving average price of $6.15. The stock has a market cap of $745.72 million, a PE ratio of -3.08 and a beta of 0.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52-week low of $3.73 and a 52-week high of $17.39.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. Equities research analysts forecast that uniQure will post -3.74 earnings per share for the current year.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of uniQure by 11.4% during the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after acquiring an additional 109,740 shares in the last quarter. SG Americas Securities LLC acquired a new position in uniQure during the second quarter worth $79,000. Clear Harbor Asset Management LLC boosted its position in uniQure by 35.2% during the second quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 12,500 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in uniQure in the second quarter valued at $815,000. Finally, Privium Fund Management B.V. increased its position in shares of uniQure by 10.6% in the second quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock valued at $2,869,000 after buying an additional 61,501 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.